Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Breast cancer subtypes and outcomes of central nervous system metastases.

Arslan UY, Oksuzoglu B, Aksoy S, Harputluoglu H, Turker I, Ozisik Y, Dizdar O, Altundag K, Alkis N, Zengin N.

Breast. 2011 Dec;20(6):562-7. doi: 10.1016/j.breast.2011.07.017. Epub 2011 Aug 25.

PMID:
21871802
2.

Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.

Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, Wada N.

Oncology. 2013;84(3):135-40. doi: 10.1159/000345321. Epub 2012 Dec 11.

PMID:
23235554
3.

Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.

Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E.

Cancer. 2007 Dec 15;110(12):2640-7.

4.

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.

Cancer. 2006 Aug 15;107(4):696-704.

5.

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA.

Clin Cancer Res. 2011 Jul 15;17(14):4834-43. doi: 10.1158/1078-0432.CCR-10-2962.

6.

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.

Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN.

Cancer. 2004 Oct 15;101(8):1760-6.

7.
8.

Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.

Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crinò L.

Oncologist. 2007 Jul;12(7):766-73.

9.

Central nervous system metastases in women after multimodality therapy for high risk breast cancer.

Carey LA, Ewend MG, Metzger R, Sawyer L, Dees EC, Sartor CI, Moore DT, Graham ML.

Breast Cancer Res Treat. 2004 Dec;88(3):273-80.

PMID:
15609130
10.

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, García-Conde J, Baselga J, Clinton GM.

Clin Cancer Res. 2006 Jan 15;12(2):424-31.

11.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
12.

[Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].

Wang YJ, Wang N, Wang B, Qin WX, Xue CY.

Zhonghua Zhong Liu Za Zhi. 2009 May;31(5):346-50. Chinese.

PMID:
19799082
13.

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.

Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW.

Cancer. 2008 Jun;112(11):2359-67. doi: 10.1002/cncr.23468.

14.
15.

Brain metastases in breast cancer: prognostic factors and management.

Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, Kim SB, Kim WK.

Breast Cancer Res Treat. 2008 Oct;111(3):523-30. Epub 2007 Nov 8.

PMID:
17990100
16.

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.

Cancer. 2003 Jun 15;97(12):2972-7.

17.

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.

Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B.

J Clin Oncol. 2006 Dec 20;24(36):5658-63. Epub 2006 Nov 13.

PMID:
17102066
18.

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.

Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.

Cancer Chemother Pharmacol. 2009 Jan;63(2):275-80. doi: 10.1007/s00280-008-0737-3. Epub 2008 Apr 1.

PMID:
18379783
19.

Seven cases of breast cancer recurrence limited to the central nervous system without other visceral metastases.

Higashi H, Fukutomi T, Watanabe T, Adachi I, Narabayashi M, Shibui S, Hokamura N, Akashi-Tanaka S.

Breast Cancer. 2000;7(2):153-6.

PMID:
11029788
20.

Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge.

Stemmler HJ, Heinemann V.

Oncologist. 2008 Jul;13(7):739-50. doi: 10.1634/theoncologist.2008-0052. Epub 2008 Jul 9. Review.

Supplemental Content

Support Center